18th Annual Controversies in Modern Eye Care
May 4, 2024
Register Now!
Heading to ARVO? You’re invited to dinner COPE CE/CME. Or join virtually!
May 6 & 7, 2024
Register Now!
(COPE Credit) Community Practice Connection™: Paradigm Shifts in Presbyopia – Understanding Advances in Topical Treatment Innovations
View More
(CME Credit) Learning About the Lid – Optimizing Recognition, Diagnosis, and Treatment of Demodex Blepharitis & Blepharoptosis
View More
2nd Annual IKA Keratoconus Symposium: Front to Back and Everything in Between
May 18-19, 2024
Register Now!
(COPE Credit) Learning About the Lid – Optimizing Recognition, Diagnosis, and Treatment of Demodex Blepharitis & Blepharoptosis
View More
(CME Credit) Virtual Case Studies™ in Cataract Surgery: Selecting Surgical Techniques and Preventing Intra-Operative Complications
View More
Neurotrophic Keratitis Management: How Early Intervention Can Make a Difference
View More
A Case of Neovascular AMD With Treatment-Resistant Pigment Epithelium Detachment
May 3rd 2024Adiel Smith, MD, FASRS, presents the case of a patient with neovascular age-related macular degeneration (nAMD) with treatment-resistant pigment epithelium detachment, and the panel offers clinical insights on treatment decisions.
According to the company, a subretinal injection of ATSN-201 was well tolerated in all patients in the first cohort with extensive resolution of schisis observed in 2 patients. Safety data from the first cohort of the LIGHTHOUSE study will be presented at the Retinal Cell and Gene Therapy Innovation Summit 2024 being held May 3, 2024, in Seattle.
Aurion Biotech completes dosing of all subjects in Phase 1/2 CLARA trial
May 1st 2024The trial is evaluating AURN001, a combination cell therapy product comprised of neltependocel (allogeneic human corneal endothelial cells [CECs]) and Y-27632 for the treatment of corneal edema secondary to corneal endothelial dysfunction.